Elemam, Noha MMekky, Radwa YRashid, GowharBraoudaki, MariaYouness, Rana A2024-02-082024-02-082024-01https://doi.org/10.1017/erm.2023.26http://repository.msa.edu.eg/xmlui/handle/123456789/5837The host immune system status remains an unresolved mystery among several malignancies. An immune-compromised state or smart immune-surveillance tactics orchestrated by cancer cells are the primary cause of cancer invasion and metastasis. Taking a closer look at the tumour-immune microenvironment, a complex network and crosstalk between infiltrating immune cells and cancer cells mediated by cytokines, chemokines, exosomal mediators and shed ligands are present. Cytokines such as interleukins can influence all components of the tumour microenvironment (TME), consequently promoting or suppressing tumour invasion based on their secreting source. Interleukin-10 (IL-10) is an interlocked cytokine that has been associated with several types of malignancies and proved to have paradoxical effects. IL-10 has multiple functions on cellular and non-cellular components within the TME. In this review, the authors shed the light on the regulatory role of IL-10 in the TME of several malignant contexts. Moreover, detailed epigenomic and pharmacogenomic approaches for the regulation of IL-10 were presented and discussed.enCancer; Cytokines; IL-10; Interleukins; Non-coding RNAs; Pharmacogenomics; Tumour-microenvironmentArticlehttps://doi.org/10.1017/erm.2023.26